Scinovex
review Open AccessTop 1% cited

Minireview: The OPG/RANKL/RANK System

Endocrinology · 2001 · Vol. 142(12) · pp. 5050–5055
Sundeep Khosla

Abstract

The identification of the OPG/RANKL/RANK system as the dominant, final mediator of osteoclastogenesis represents a major advance in bone biology. It ended a long-standing search for the specific factor produced by preosteoblastic/stromal cells that was both necessary and sufficient for osteoclast development. The initial cloning and characterization of OPG as a soluble, decoy receptor belonging to the TNF receptor superfamily was the first step that eventually led to an unraveling of this system. Soon thereafter, the molecule blocked by OPG, initially called OPG-ligand/osteoclast differentiating factor (ODF) and subsequently RANKL, was identified as the key mediator of osteoclastogenesis in both a membrane-bound form expressed on preosteoblastic/stromal cells as well as a soluble form. RANKL, in turn, was shown to bind its receptor, RANK, on osteoclast lineage cells. The decisive role played by these factors in regulating bone metabolism was demonstrated by the findings of extremes of skeletal phenotypes (osteoporosis vs. osteopetrosis) in mice with altered expression of these molecules. Over the past several years, work has focused on identifying the factors regulating this system, the signaling mechanisms involved in the RANKL/RANK pathway, and finally, potential alterations in this system in metabolic bone disorders, from the extremely common (i.e. postmenopausal osteoporosis) to the rare (i.e. familial expansile osteolysis).

Bone Metabolism and DiseasesBone health and treatmentsBone health and osteoporosis researchRANKLOsteoclastStromal cellOsteoprotegerinRANK LigandMediatorOsteoporosisBone remodelingBone resorptionInternal medicine

MeSH terms

AnimalsBone Diseases, MetabolicCarrier ProteinsCell DivisionGlycoproteinsHumansMembrane GlycoproteinsOsteoclastsReceptors, Tumor Necrosis FactorReceptors, Cytoplasmic and NuclearOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa B

Funding

  • U.S. Public Health Service
  • National Institute on Aging
Citations
1,404
FWCI
14.47
field-weighted impact
References
65
Percentile
99%
vs. same field & year
Citations per year
Cited by
Mayo Clinic Proceedings
Mayo Clinic Proceedings · 2000 · 2,229 citations
Osteoblast physiology in normal and pathological conditions
Cell and Tissue Research · 2010 · 328 citations
Vitamin D
American Journal of Physiology-Renal Physiology · 2005 · 1,128 citations
Inflammation, fracture and bone repair
Bone · 2016 · 1,242 citations
Silk fibroin as biomaterial for bone tissue engineering
Acta Biomaterialia · 2015 · 762 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Minireview: The OPG/RANKL/RANK System · Scinovex